Welcome to the 2021 annual meeting of stockholders of Myriad Genetics, Inc. I'm Louise Phanstiel, Chair of the Board of Directors, and it is my pleasure to welcome you. It is 8:00 A.M. Mountain Standard Time, and in accordance with the notice of the meeting, I call to order the 2021 annual meeting of stockholders of Myriad Genetics. On the website, there's an agenda for the meeting and rules of conduct. We will conduct this meeting in accordance with the agenda and those rules. There will be an opportunity for questions later in the webcast. Please adhere to the rules of conduct attached to your agenda in asking questions or making comments at that time. Before proceeding to the business of the meeting, I'd like to introduce you to our directors, including those who are up for election this year. Paul J. Diaz. Diaz joined Myriad as a Director and our Chief Executive Officer in August 2020. Previously, Mr. Diaz served as a partner in the private equity firm of Cressey & Company, and prior to that, he had been the CEO and Vice Chairman of Kindred Healthcare. Heiner Dreismann, PhD, joined Myriad as a Director in June of 2010. Dr. Dreismann was formerly the President and CEO of Roche Molecular Systems. Rashmi Kumar was appointed as a Director of the company in September 2020. Ms. Kumar currently serves as the Senior Vice President of Global Information Technology at Hewlett Packard Enterprise. Dennis H. Langer, M.D., J.D., has been a Director of Myriad since May 2004. He has served in various capacities in several major pharmaceutical companies, including GlaxoSmithKline, Eli Lilly, and Abbott. He is also a clinical professor at the Department of Psychiatry, Georgetown University School of Medicine. Lee N. Newcomer, MD, joined the board of Myriad Genetics in September 2019. He previously held multiple executive positions at UnitedHealthcare, including Chief Medical Officer. Colleen F. Reitan was appointed to our board of directors in September 2019. She previously served as the Chief Operating Officer of Health Care Service Corporation. Daniel M. Skovronsky, MD, PhD, has served as a director since July 2020. Dr. Skovronsky currently serves as the Chief Scientific Officer and President of Lilly Research Laboratories at Eli Lilly. Daniel K. Spiegelman has been a director since May 2020. Mr. Spiegelman previously served as Executive Vice President and Chief Financial Officer at BioMarin Pharmaceutical. I joined the Myriad board of directors in September 2009 and have served as Chair of the Board since March 2020. I previously held several senior positions at WellPoint Inc., including Chief Financial Officer for all WellPoint Inc. subsidiaries. A more detailed description of each of our directors, including their history with the company, is included in the proxy materials. I'm also pleased to announce that we have the executive team of Myriad Genetics joining us on the webcast today. Biographical information for each of our officers, including their histories with the company, is included in the proxy materials. If questions arise during the discussion period that these people should appropriately address, they will be glad to respond. Also with us today representing Ernst & Young, the company's independent auditors, is Mark Belfance. This meeting is held pursuant to a notice to each stockholder of record at the close of business on April 8th, 2021, which was made available on the internet and mailed to certain stockholders on or about April 15th, 2021. Only stockholders of record at the close of business on April 8th are entitled to vote at this meeting. I now ask that our Inspector of Elections, Nathan Snipes, report on the presence of a quorum. On April 8th, 2021, the number of shares of common stock issued and outstanding and entitled to vote was 77,000,430. A majority of these shares, or 38,500,216 shares, constitutes a quorum. Substantially in excess of that number of shares is represented at this meeting, either in person or by proxy. Thank you, Nathan. I hereby declare a quorum present at the meeting. On behalf of the board of directors of the company, thank you to all stockholders who completed their proxy. If you are a stockholder of record on April 8, 2021, and wish to vote now, you can do so by utilizing the interface on the webcast page by hitting the Vote button. It is currently 8:04 A.M. Mountain Standard Time, and the polls are now open. The first matter to be acted upon by stockholders is the election of directors. Louise Phanstiel, Daniel M. Skovronsky, M.D., Ph.D., and Daniel Spiegelman have been nominated by the board for election at this meeting to serve as directors in Class 1. The Class 1 director's term will end at the annual meeting to be held at 2024. I've introduced the nominees, and additional information about the nominees is contained in the proxy statement. I declare the Class 1 directors duly nominated. The company has not received notice of any other nominations as required under the bylaws. Therefore, the nominations are closed. For stockholders voting on the webcast, please do so now. The second matter being submitted to stockholders for action is the ratification of the selection by the Audit and Finance Committee of the board of directors of Ernst & Young LLP as auditors of the company's financial statements for the fiscal year ending December 31st, 2021. Dan Spiegelman, Chair of the Audit and Finance Committee, will now read the recommendation from the Audit and Finance Committee in this regard. The Audit and Finance Committee of the Board of Directors is assigned the responsibility of appointing the company's auditors. The committee consists entirely of directors who are independent of corporate management. In its deliberations, the committee took note of the fact that the committee has worked closely and met on a regular basis with Ernst & Young during the year, and the committee had substantial opportunity to evaluate their work and found it to be satisfactory. The Audit and Finance Committee recommends the ratification of its appointment of Ernst & Young to audit the financial statements for the fiscal year ending December 31st, 2021. Thank you, Dan. Representatives from Ernst & Young will be available to answer questions during the question- and- answer session later in the webcast. Stockholders voting on the webcast, please do so now. The next matter to be acted upon by stockholders is an advisory vote on the compensation of the company's named executive officers. Detailed disclosures regarding the company's compensation policies can be found in the proxy statement under the section entitled Compensation Discussion and Analysis. Because this vote is advisory, the results will not be binding on the company's Compensation and Human Capital Committee or Board of Directors. However, both the Compensation and Human Capital Committee and the Board will review the voting results and take them into consideration when making future decisions regarding the compensation of the company's named officers. Stockholders voting on the webcast, please do so now. It is 8:07 Mountain Standard Time. The polls are now closed for each of the matters voted on at this meeting. Will the Inspector of Elections please report the results of the balloting? Thank you. We have completed a preliminary count of all the ballots and present the following. For proposal number one, election of directors, a majority of the shares voted was cast for the election of S. Louise Phanstiel, Daniel M. Skovronsky, MD, PhD, and Daniel Spiegelman to serve until the 2024 annual meeting. The results of the voting for proposal number two, appointment of the auditors, are 67,469,474 votes cast for the ratification of the appointment of Ernst & Young LLP to serve as the company's independent public accountants for the fiscal year ending December 31st, 2021, which is more than a majority of the shares voted with respect to this proposal. The results of voting for proposal number three, an advisory vote on the compensation of the company's named executive officers, are 62,380,220 votes cast for the proposal or in support of the compensation of our named executive officers, which is more than a majority of shares voted with respect to this proposal. Thank you, Nathan. Subject to final vote tabulation, I hereby declare that the nominees for directors have been duly elected, the appointment of Ernst & Young as the company's independent public accounting firm to audit the company's financial statements for the fiscal year ending December 31st, 2021, has been duly ratified, and a majority of the shares voted on the advisory vote regarding the compensation of the company's named executive officers, as disclosed in the proxy statement, have been voted in favor of compensation of the company's named executive officers. After the final tabulation of votes has been completed, the results will be filed on Form 8-K and will be placed in the minutes of this meeting. This concludes the formal portion of our meeting. I would again like to express my appreciation to the stockholders who have attended the meeting and voted, as well as those who have submitted their proxies but were not able to be present in person via this webcast. The meeting is now formally adjourned. We now invite you to ask any questions that you may have. We will only take questions from stockholders of record or an individual or entity named in a proxy statement given by a stockholder of record as of April 8th, 2021, and properly filed with the corporate secretary prior to the meeting. Please be advised that management's remarks and responses to questions and comments may contain some forward-looking statements. In compliance with the Private Securities Litigation Reform Act of 1995, I caution you that actual results may differ significantly and adversely from results discussed in the forward-looking statements. Forward-looking information is inherently subject to risks and uncertainties that could cause results or events to differ materially and adversely from those described and/or implied by forward-looking statements due to a variety of factors and risks. Factors and risks that might cause such a difference include those set forth from time to time in the company's SEC filings, including the transition report on Form 10-K for the six months ended December 31, 2020, and in reports on Form 10-Q and Form 8-K filed with the SEC. With that, Nathan, do we have any stockholder questions? There are no stockholder questions at this time. Thank you all for attending today's stockholder meeting of Myriad Genetics. The conference is now concluded. Thank you for attending today's presentation. You may now disconnect.